Current Edition

news

Sparks sells regulatory fast pass to Jazz for $110M

Brief: Spark Therapeutics has sold a priority review voucher (PRV) to Jazz Pharmaceuticals for $110 million, according to a Monday disclosure. While details were scant, …

Continue Reading →